<DOC>
	<DOCNO>NCT02037997</DOCNO>
	<brief_summary>The purpose study evaluate compare safety effectiveness Chemotherapy Combination With Erlotinib , Sequential Erlotinib Treatment Patients With EGFR - TKI Resistance EGFR Mutations</brief_summary>
	<brief_title>Safety Effectiveness Study Chemotherapy Combination With Erlotinib , Sequential Erlotinib Treatment Patients With NSCLC</brief_title>
	<detailed_description>first cycle treatment ( day one ) two month last cycle</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Sign inform consent 2 . ≥18 year 3 . According RECIST 1.1 standard , least one measurable lesion 4 . Histology cytology confirm unfavorable surgical locally advanced stage ( stage IIIB ) metastatic NSCLC ( IV ) , Sensitive EGFR gene mutation 5 . Palliative treatment receive two medicine firstline platinumbased chemotherapy EGFR TKI secondline treatment objective clinical benefit ( CR , PR SD 6 month ) , RESIST standard curative effect evaluation progress 6 . PS=0,1,2 7 . No serious blood , heart , lung , liver kidney dysfunction , immune deficiency 8 . Hb≥9g/dL；WBC≥3*109/L，ANC≥1.5*109/L，PLT≥75*109/L 9 . Men woman childbearing age experiment willing take contraceptive measure 10 . Estimated survival period 3 month 1 . The palliative chemotherapy ever use docetaxel pemetrexed 2. small cell lung cancer non small cell hybrid 3 . Women pregnancy lactation 4 . In past antitumor treatment outstanding ease &gt; CTCAE 2 level toxicity 5 . Ccr &lt; 30 ml/min ( calculate CockcroftGault formula ) 6. hepatic insufficiency： Tbil &gt; 1.5×ULN ALT AST &gt; 2.5×ULN ( Patients liver metastasis &gt; 5×ULN ) Alkaline phosphatase＞2.5 ×ULN ( Patients liver metastasis &gt; 5×ULN ) 7 . Severe symptomatic heart disease 8 . Symptomatic brain metastasis 9 . In last 5 year suffer histological type malignant tumor 10 . There serious uncontrolled systemic disease 11 . During study period plan radiotherapy target lesion 12 . During study period , plan use antineoplastic therapy 13 . Clinical study treatment 30 day begin period prior participate study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>PFS</keyword>
</DOC>